Investor Relations

Overview

Advaxis, Inc. (NASDAQ: ADXS)

Advaxis is a clinical stage biotechnology company focused on the development of immunotherapies to treat multiple different types of cancers. We are currently conducting clinical trials with our lead product candidate, ADXS-HPV, in HPV-associated cervical cancer (late-stage trials), head and neck cancer (Phase 1/2) and anal cancer (Phase 1). Our second lead product candidate is ADXS-cHER2, which we intend to develop for pediatric osteosarcoma and other HER2 overexpressing cancers, such as breast cancer. We intend to develop our third product candidate, ADXS-PSA, for prostate cancer, as well as explore the potential to combine any of our proprietary immunotherapies in combination with other anticancer therapies. Advaxis has three commercial partnerships with other major biopharmaceutical companies for the development and commercialization of our proprietary cancer immunotherapies in countries outside the U.S. and for the global animal-health oncology market. Advaxis has crea ted and is developing more than 20 distinct immunotherapies based on its proprietary platform, either directly or through strategic collaborations with recognized cancer centers of excellence.

Investor Relations

Gregory T. Mayes
Chief Operating Officer
Advaxis, Inc.
305 College Rd East
Princeton, NJ 08540
T: 609-452-9813 ext 102
F: 609-452-9818
mayes@advaxis.com

Stock Quote

Recent News

Advaxis to Receive $1.7M Through New Jersey Technology Business Tax (NOL) Program

Read More

Advaxis Submits Investigational New Drug Application for Phase 1/2 Study of ADXS-HPV and MedImmune's MEDI4736 for the Treatment of HPV-Associated Cervical and Head & Neck Cancer

Read More

Advaxis Submits Investigational New Drug Application for ADXS31-142 (ADXS-PSA) for the Treatment of Metastatic Castration Resistant Prostate Cancer

Read More